Analysts’ Opinions Are Mixed on These Healthcare Stocks: Dexcom (DXCM), Revolution Medicines (RVMD) and Incyte (INCY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM), Revolution Medicines (RVMD) and Incyte (INCY).
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Revolution Medicines (RVMD)
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Revolution Medicines yesterday and set a price target of $185.00. The company’s shares closed last Monday at $148.49.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revolution Medicines with a $182.78 average price target, implying a 21.8% upside from current levels. In a report issued on May 30, TipRanks – Google also upgraded the stock to Buy with a $175.00 price target.
Incyte (INCY)
In a report released yesterday, Derek Archila from Wells Fargo maintained a Hold rating on Incyte, with a price target of $101.00. The company’s shares closed last Monday at $100.64.
According to TipRanks.com, Archila is a 5-star analyst with an average return of
Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $109.93, which is a 7.0% upside from current levels. In a report released yesterday, William Blair also maintained a Hold rating on the stock.
Read More on DXCM:
